leadf
logo-loader
viewe-Therapeutics PLC

e-Therapeutics resumes US brain cancer trial recruitment

drug_research_350_536b29c6134d2.jpg

E-Therapeutics (LON:ETX) has resumed recruitment of patients in its phase 1a trial of its brain cancer drug, ETS2101. after the all-clear from the US regulator.

Recruitment was halted due to a drug storage issue but after the clearance from the US Food and Drug Administration the trial will now continue with higher doses in further cohorts of patients. 

Patients who had received treatment with ETS2101 at the time of the temporary halt in recruitment were able to continue to be dosed in accordance with trial protocols.

The trial is being conducted at the University of California San Diego Moores Cancer Centre.

A UK trial is also underway into the use of the ETS2101 (dexanabinol) in a variety of solid tumours.

Quick facts: e-Therapeutics PLC

Price: 13.875 GBX

AIM:ETX
Market: AIM
Market Cap: £58.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read